June 28, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the preclinical and the phase 1 clinical trial results of its ETa antibody Getagozumab at the Pulmonary Hypertension Association (PHA)’s 2018 International PH Conference and Scientific Sessions. The 2018 PHA’s International PH Conference and Scientific Sessions will take place in Orlando, June 29 -July 1, 2018.

Poster Number 1013: Getagozumab: A Therapeutic Monoclonal Antibody Targeting Endothelin Receptor A for Pulmonary Arterial Hypertension